Josh Schimmer
PersonHeard in 1 episode across 1 show since Oct 2026
Josh Schimmer is a biotech equity research analyst at Cantor Fitzgerald and Co. He is known for analyzing biotechnology companies and for co-hosting Biotech Hangout, a live discussion program focused on the life sciences industry.
Episodes
First heard
Guest appearances
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Nov 2025 | 0 |
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 0 |
| Oct 2026 | 1 |
Email alert
Email me when Josh Schimmer comes up on a podcast
One email a week at most, with the new episodes that mention Josh Schimmer. Free, no account needed, unsubscribe in one click.
What Josh Schimmer has said on podcasts
4 statements
Biotech sector fundamentals remain strong despite bearish trading conditions.
“the fundamentals still seem really, really strong”
Open the episode · Episode 200 - October 23, 2026Listen at 13:20
Biotech is increasingly profitable, revenue-generating, and attractive to generalist investors.
“the sector itself is incredibly well positioned, increasingly profitable, increasingly revenue generating, increasingly appealing”
Open the episode · Episode 200 - October 23, 2026Listen at 13:32
Higher launch prices have helped biotech companies become profitable and more investable.
“that's actually changed quite dramatically thanks to Much higher launch prices, companies vaulting into profitability in the sector”
Open the episode · Episode 200 - October 23, 2026Listen at 55:11
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
1 episode featuring Josh Schimmer, newest first
